TPST Latest Press Releases

-- September 23, 2026 --

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors Globe Newswire 8:00 AM

-- September 15, 2026 --

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform Globe Newswire 4:05 PM

-- September 11, 2026 --

Tempest Therapeutics Announces Up to $7.5 Million Private Placement Globe Newswire 8:00 AM

-- September 8, 2026 --

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 8:30 AM

-- August 13, 2026 --

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:25 PM

-- July 21, 2026 --

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T Globe Newswire 7:00 AM

-- July 15, 2026 --

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 Globe Newswire 7:00 AM

-- June 4, 2026 --

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors Globe Newswire 4:37 PM

-- May 29, 2026 --

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds Globe Newswire 8:00 AM

-- May 14, 2026 --

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:15 PM

Market Data Delayed 15 Minutes